Taiwan Advance Bio-Pharmaceutical Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced total revenue was TWD 205.802 million compared to TWD 168.351 million a year ago. Operating loss was TWD 154.697 million compared to TWD 154.774 million a year ago. Net loss was TWD 174.667 million compared to TWD 133.196 million a year ago. Basic loss per share was TWD 2.3 compared to TWD 2 a year ago.